Common Painkillers Raise Heart Death Risk
Ibuprofen Increases Stroke Risk; Diclofenac as Risky as Vioxx, Study Finds
WebMD News Archive
June 8, 2010 -- High doses of common painkillers raise the risk of heart death in healthy people, a huge Danish study finds.
It's the first evidence that so-called NSAID (nonsteroidal anti-inflammatory drug) pain relievers -- including some sold over the counter -- increase the risk of heart disease and death in people without underlying health conditions.
The risks are dose related and are mostly associated with high doses of the drug. However, for most of the drugs, the deaths occurred in people who had been taking the drugs for only two weeks.
"We found that most NSAIDs are associated with increased cardiovascular mortality and morbidity," says researcher Emil Loldrup Fosbol, MD, of Gentofte University Hospital in Hellerup, Denmark.
The study's most disturbing finding: Diclofenac (brand names include Cataflam, Voltaren) is as risky as the now-banned Vioxx. Both diclofenac and Vioxx nearly doubled the risk of death from heart disease among healthy people in the Fosbol study.
Although diclofenac is available in the U.S. only by prescription, it's sold over the counter in many nations.
Ibuprofen Heart Risk
Perhaps of concern to more Americans is the finding that ibuprofen (brand names include Advil and Motrin) increased risk of stroke by about 30% in the Fosbol study.
Although low doses of ibuprofen seemed to lower the risk of heart attack, the study found a trend toward increased heart attack risk with high doses (more than 1,200 milligrams per day or more than two 200 milligram pills three times daily).
Based on other evidence, an American Heart Association panel in 2007 warned that treating chronic pain with NSAIDs other than aspirin increases a person's risk of heart attack and stroke. The lead author of that AHA statement, Elliot M. Antman of Harvard Medical School and Brigham and Women's Hospital, says the Fosbol findings underscore the importance of those recommendations.
"Doses examined in this new study were very similar to doses that patients are likely to encounter both at the over-the-counter level and the prescription level," Antman says in a news release.
The silver lining to the Fosbol study is that naproxen (brand names include Aleve and Naprosyn) does not appear to carry any risk of heart disease or stroke.